Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Rod, Thanks for putting that ibox together. Very handy.
I, too felt that the CC was full of exciting stuff. We've got goalposts to look forward to both near and long term. That last analyst though, was a real wet blanket. The implications of his questions were that management's strategic plan was nothing to be excited about. Unfortunately, Lim and Co., in typical techno-science geek fashion, missed the social cues of this conversation and failed to slap him down. The result was that the CC ended with a whimper rather than on a note of progress and optimism, hence the corresponding drop in the pps. Good times ahead, though, IMHO.
-Fritz
Siri:
look at a one year chart of NURO for an example of the consequences after Texas medicare decided its neurology tests were NOT reimbursable.
-Fritz
So the first program is one that we are publicly disclosing for the first time on this call. We have initiated and nearly completed an ongoing clinical trial in a therapeutic area that represents a multi-billion dollar market. This Phase I prospective randomized trial is designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of two different marketed therapeutic recombinant proteins when subcutaneously co-injected with and without PH20.
It is anticipated that based on the existing pre-clinical study data with three different molecules co-injected with PH20 in more than one animal species, as well as based on several completed clinical trials of therapeutic agents that have been co-injected with PH20, which we've reported previously with morphine and Humira for instance. We believe that PH20 will favorably alter the absorption parameters of these proteins. Now what does this mean?
Well, if the co-injection is well tolerated, and the anticipated alteration in PK and PD is observed, the existing body of clinical knowledge for this particular therapeutic area suggests that the proposed combination product including PH20 may provide a therapeutic strategy that would result in meaningful clinical benefit for patients. The commercial implications are that, we could potentially develop a best-in-class therapeutic within an existing multi-billion dollar market.
Anyone care to speculate just what the "two different marketed therapeutic recombinant proteins" are?
Link to transcript of today's CC:
http://seekingalpha.com/article/68609-halozyme-therapeutics-q4-2007-earnings-call-transcript?source=yahoo&page=2
Who was that last questioner? I didn't get his name and organisation.
-Fritz
Thanks! Interesting...
What's the hot board?
-Fritz
That little 117 buy @.69 was like a shot of steroids for my portfolio! LOL! A little goes a long way.
-Fritz
That's Mary Ann, not Ginger. I always suspected Mary Ann was the real party girl. The professor was no fool.
-Fritz
Yes, Minx,
Rod, in fact, speculated a few months ago on the Yahooligans board that Kirk was constrained from buying because of insider info. The recent Jeffries analysis confirms this. Now we're starting to get a little wiff of just what these things might be!
-Fritz
Limitations on Kirk:
We have all noted that Kirk stated in the Jeffries interview that he would love to be a buyer at these levels but is prohibited from doing so. Since the change in the company by-laws allowing him to increase the percentage of his holdings he has not made a move.
It seems to me that there must be some kind limit on the SEC regs, otherwise he would be barred permanently from buying. I'm not sure of the details here. Does anyone know when he could be expected to be permitted to fulfill his wish?
=Fritz
...but then how is it possible that he thinks the ultimate driver is sure to be some internally developed products which, like any such biotech products, probably have a relatively low chance of successfully getting through the trial process, getting approved, and getting marketed within 5 or 10 or 15 years, and which will require large expenditures by HALO along the way? I don't get it. Do you?
Hew:
In regards to your quoted portion above:
I feel that there is much less regulatory uncertainty with HALO's products as compare to the typical NDA. HALO's pipeline is more in the nature of adjuvants which are by nature (IMHO) less risky than a primary drug, and as a result pass through the regulatory process relatively more quickly. Thus the concurrent possibilities of maximized partnership along with a few blockbuster in-house products are not inherently contradictory.
Good luck!
-Fritz
Thanks, Minx
gophred at operamail.com
Probably the same guy:
*Both newborn ID's.
*Both ID's compound words.
*In possession of the identical info.
LOL!
-Fritz
3. " He expects news flow from these programs [internal programs] throughout 2008, increasing visibility."
I expect, based on that statement and the recent PR, that the news flow he mentions will begin this Friday.
Good luck!
=Fritz
Sea-Note:
Thanks for adding your expertise here. This is a stellar board and you add to its lustre.
Best of luck!
-Fritz
New hires will certainly turn up the fire on the burn rate. I hope they can offset that with some meaty news on Friday.
-Fritz
Hew: That's an observation that I completely agree with but a caveat:
This "analysis" from Jeffries has always given me some pause.
It was dropped on the board by a poster who was completely unknown to us and if I recall correctly, his alias was newly born. He has not been back since and has no history of other posts on Yahoo. Do you feel that this is a legit document?
-Fritz
PS: Welcome, Siri! Don't be a stranger here!
Looks good, Rod.
Perhaps they will address this study and others during the pipeline update on Friday.
Speaking of the upcoming conference call, I found today's PR a bit curious in that they've never overtly referenced the pipeline in the previous PRs. Do you think that they may have something meaty to share with us?
-Fritz
Baxter Alzheimer's drug data positive - analyst
=======================================================
Apparently the US newsfeeds pulled this info under threat of litigation.
Here is an article from the UK
-Fritz
=======================================================
http://www.guardian.co.uk/feedarticle?id=7357471
=======================================================
* Reuters
* , Tuesday March 4 2008
CHICAGO, March 4 (Reuters) - Results of a small study of Baxter International Inc's Gammagard IGIV product in Alzheimer's patients are positive and worth tracking, according to a JPMorgan analyst, citing abstracts released ahead of a neurology meeting.
The study, conducted at Weill Cornell Medical College in New York City, involved 24 patients with mild to moderate Alzheimer's disease who received either Gammagard immunoglobulin therapy or a placebo for six months.
Study participants treated with IGIV had "significantly better" outcomes than those who received a placebo based on cognitive functioning measures, said JPMorgan analyst Michael Weinstein, citing the study data. The data did not reach statistical significance due to the small number of patients studied, he said.
Weinstein noted only headlines of the Phase II study were divulged, but called the information encouraging.
A Baxter spokesman said the company and Cornell would release final data on the Phase II Alzheimer's study in mid-April at the American Academy of Neurology's annual meeting in Chicago.
Baxter and Cornell released preliminary results of the study in September and said the trial's favorable outcome met the threshold for proceeding to a Phase III study. The company is in the process of finalizing the Phase III trial protocol, a Baxter spokesman said.
Baxter's Gammagard IGIV liquid is approved to treat primary immunodeficiency disorders.
"While Baxter understands the excitement around the Phase II study, Baxter wants to emphasize additional research is required to explore Gammagard liquid's potential as a safe and effective treatment for Alzheimer's disease," Baxter spokesman Chris Bona said.
Weinstein said he expects Baxter to generate close to $2 billion in free cash flow in 2008, buy back another $1 billion in stock and boost its dividend.
Late in the session, Baxter shares were up 48 cents or 0.8 percent at $59.48. (Reporting by Susan Kelly, editing by Gerald E. McCormick)
Business
Thanks! I have taken a small position. Got in a few days ago at .165.
I am definitely intrigued by the Airship concept. I think this is going to have legs.
Considering a larger position here but, as I said, I am trying to fill in some blanks. Company PR only references a deal for marketing rights but no other info was given. Any clues here would be appreciated!
Good luck!
-Fritz
Here's how I conduct my DD:
1. Filings first.
2. Company PR's second.
3. Message boards dead last. LOL!
I'm just trying to fill in some blanks here since the PR's were a little thin on details of the relationship between the two entities.
I was specifically interested in SmallCapNYC's statement regarding "$4 million back to the company". Not sure what that meant or where it came from.
(Disclaimer: I do have ADD so my apologies if I missed something in the PR's. LOL)
Thanks!
-Fritz
Yes, I read it but don't see WNRC mentioned. Only Airships.
-Fritz
SmallcapfundNYC:
Could you explain this? I don't understand this statement.
Thanks!
-Fritz
Weiss Multistrategy LLC showing up on the top 10 institutional holdings on the S&P research tonight. FWIW
Yes, I noticed that. But you read it here (on this MB) first!
Good luck to all.
-Fritz
Roche CEO stepping down
Hopefully this is on-topic LOL!
http://www.reuters.com/article/marketsNews/idUKL0438053020080304?rpc=44
-Fritz
Hey all: What is the financial arrangement between WNRC and Airship Surveillance?
The various PR's that I've read are not clear on this point.
Thanks and good luck!
-Fritz
Authorized shares are 200,000,000.
Outstanding shares number about 67,000,000 at this time.
Since mid-February it's worth noting that it appears that a buyer has accumulated approximately 2 million shares, a significant percentage of the O/S. The buyer is not buying all at once, of course, but has made the buys in large blocks at various days.
It will be interesting to see if this continues. If the buyer crosses the 10% threshold we'll eventually get a filing and find out who it is.
Also, notice that the pps has not been not sagging even in the face of a challenging overall market. This shows that ESNR shares are in pretty strong hands, IMHO.
Interesting times...
-Fritz
Another high volume day. With the price stable this is clearly accumulation as opposed to dumping. A very good sign IMHO.
As they say, price follows volume.
Good Luck!
-Fritz
Yo, Rod!
Nice board ya got here! LOL!
Seriously, transferring to this board is a good idea and the best way to get the discussion back on track.
Yahoo is a joke - a haven for a pitiful type of anti-social characters. They can quickly make a board all about them if they are not quarantined and ignored. There are a few such elements here at I-Hub but they are not tolerated for very long, as you know.
OT - check the board at DPDW. Great play. Great DD by the regulars.
I believe fair market value will soon be demonstrated to be between $1.00-1.50 near term, with a huge upside longterm.
Good luck!
-Fritz
Seems that they've nailed the concept of small contracts pretty well. LOL!
Time to step up and get in the big leagues. I'm thinking the Asian market will prove to be the first to bear some fruit.
I'm sceptical of the domestic homeland security opportunities at this point. It seems that the DoHS would have been a large customer by now.
Good luck!
-Fritz
For weeks and weeks this guy pretended to have inside info.
That should always be your first clue in assessing a poster's credibility.
His recent about face is your second clue, Do you need a third?
Ignore this troll and he will go play somewhere else.
Good luck.
-Fritz
Thanks, guys.
All positive info, IMHO.
Good luck!
-Fritz
So the Transfer agent is not gagged I take it?
-Fritz
SmallCAp: There are no filings as far as I have found. What are the bases for for your comments as to share structure, financing and lack of threat of typical pinkie dilution?
Thanks for sharing your opinions and info.
Regards,
-Fritz
You're not the bad guy, dude. I only said I was irked. Doesn't your wife get irked at you? Don't you get irked at your kids?
One can be irked at someone and still appreciate their finer qualities! LOL!
-Fritz
I see, BRIKK. I understand jdsgungho's dilemma. I'll contact Steve and ask that a kit be sent to me. Thanks for the suggestion. Also, thanks to jdsgungho for trying to get the info across without stepping on any toes.
-Fritz
jdsgungho: I don't see why you are being so coy about this. If IR gave you, a shareholder, an analyst's report, then it is no longer protected by any type of claimed privilege. Frankly, your lack of transparency on this topic is somewhat irksome. What is it that is preventing you from publishing the actual report on this message board? It has been days since you mentioned that Steve H. gave it to you.
-Fritz
Assessing the competition:
I get email coupons from Borders book store. Today's coupon included an opt-in option to get the same via my cell phone. I scrutinized the notice closely but couldn't see any reference to MVIV. I suspect that this offering demonstrates that MVIV has active competitors who are beating them to the punch here in the USA. Any thoughts, folks?
Good Luck!
-Fritz
What do you think of the financing?
-Fritz
No volume. Look out.
Also the PR says they are buying a chain with $7 million in '07 revenue. Paying $4 million? Can you say "bogus?" If you get in make it a quickie, IMHO.
-Fritz